Neurogene Inc. (NASDAQ:NGNE) Stock Holdings Increased by Walleye Capital LLC

Walleye Capital LLC lifted its stake in shares of Neurogene Inc. (NASDAQ:NGNE - Free Report) by 68.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,836 shares of the company's stock after acquiring an additional 30,336 shares during the period. Walleye Capital LLC owned 0.50% of Neurogene worth $1,711,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. PNC Financial Services Group Inc. acquired a new position in shares of Neurogene in the 4th quarter valued at $71,000. China Universal Asset Management Co. Ltd. acquired a new stake in Neurogene during the fourth quarter worth about $72,000. Wells Fargo & Company MN raised its holdings in shares of Neurogene by 34.5% in the 4th quarter. Wells Fargo & Company MN now owns 5,444 shares of the company's stock worth $124,000 after purchasing an additional 1,397 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Neurogene by 72.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 10,290 shares of the company's stock valued at $239,000 after purchasing an additional 4,334 shares in the last quarter. Finally, Mariner LLC acquired a new stake in shares of Neurogene in the fourth quarter worth $239,000. 52.37% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. BMO Capital Markets reduced their price target on Neurogene from $45.00 to $16.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Robert W. Baird set a $38.00 price target on Neurogene in a report on Tuesday, March 25th. William Blair restated an "outperform" rating on shares of Neurogene in a report on Tuesday, March 25th. Finally, HC Wainwright reduced their target price on Neurogene from $55.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, March 25th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $47.20.

Neurogene Stock Up 0.8 %

Shares of NGNE traded up $0.13 during mid-day trading on Friday, hitting $15.50. The stock had a trading volume of 39,570 shares, compared to its average volume of 228,192. Neurogene Inc. has a fifty-two week low of $6.88 and a fifty-two week high of $74.49. The company has a market cap of $231.34 million, a PE ratio of -3.57 and a beta of 1.46. The company's fifty day simple moving average is $13.98 and its two-hundred day simple moving average is $24.42.

Neurogene (NASDAQ:NGNE - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.05. The business had revenue of $0.93 million for the quarter. Equities analysts expect that Neurogene Inc. will post -4.27 earnings per share for the current year.

Insider Transactions at Neurogene

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the transaction, the chief financial officer now owns 72,343 shares of the company's stock, valued at approximately $1,225,490.42. This trade represents a 5.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 9.92% of the company's stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.